Tonix Pharmaceuticals Logo

  • About
    • Leadership
      • Executive Team
      • Board of Directors
    • Facilities
  • Therapeutic Areas Overview
    • Central Nervous System
      • Fibromyalgia
      • Posttraumatic Stress Disorder
      • Long Covid
      • Cocaine Intoxication
      • Migraine
      • Depression
    • Immunology
      • Organ Transplant Rejection
      • Gastro-Intestinal Cancers
    • Infectious Disease
      • COVID-19
      • Monkeypox
      • Smallpox
    • Rare Disease
      • Prader-Willi Syndrome
  • Pipeline
    • Central Nervous System
      • TNX-102 SL
      • TNX-601 ER
      • TNX-1300
      • TNX-1900
    • Immunology
      • TNX-1500
      • TNX-1700
    • Infectious Disease
      • TNX-1850
      • TNX-801
      • TNX-3600
    • Rare Disease
      • TNX-2900
    • Scientific Presentations
    • Expanded Access Policy
  • Clinical Trials
  • News & Events
    • Tonix in the News
    • Press Releases
    • Investor Presentations
    • IR Events
    • Op-eds
  • Investors
    • News & Events
    • Presentations
    • Multimedia
    • Financial Info
    • Stock Data
    • SEC Filings
    • Governance
  • Careers
  • Contact Us

Tonix is enrolling in a Phase 3 study for Fibromyalgia, and Phase 2 studies for Long COVID, Chronic Migraine, and Major Depressive Disorder. Please visit Clinical Trials.

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Tonix in the News
    • Press Releases
    • IR Events
    • Email Alerts
    • Op-Eds
  • Presentations
  • Multimedia
  • Financial Info
    • Financial Results
    • Income Statement
    • Balance Sheet
    • Cash Flow
  • Stock Data
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Tonix in the News
  • Press Releases
  • IR Events
  • Email Alerts
  • Op-Eds
Jan 4, 2023 7:00am EST

Tonix Pharmaceuticals Appoints Zeil Rosenberg, M.D., M.P.H., as Executive Vice President, Medical for Infectious Disease Programs

Jan 3, 2023 7:00am EST

Tonix Pharmaceuticals to Present at Biotech Showcase 2023

Dec 19, 2022 7:00am EST

Tonix Pharmaceuticals Achieves Enrollment of First 50 Percent of Participants in the RESILIENT Study, a Potentially Pivotal Confirmatory Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia

Dec 12, 2022 7:00am EST

Tonix Pharmaceuticals Announces Exclusive License of Potential Therapeutic or Preventative Humanized anti-SARS-CoV-2 Monoclonal Antibodies from Curia Global, Inc.

Dec 5, 2022 7:00am EST

Tonix Pharmaceuticals Announces Collaboration with Boston Children’s Hospital to Study TNX-1500 (Fc-modified anti-CD40L mAb) for the Prevention of Graft-versus-Host Disease (GvHD) Following Hematopoietic Stem Cell Transplantation in Animals

Dec 1, 2022 7:00am EST

Tonix Pharmaceuticals Presents Development Update on Potential Smallpox and Monkeypox Vaccine TNX-801 in an Oral Presentation at the World Vaccine and Immunotherapy Congress

Nov 30, 2022 7:00am EST

Tonix Pharmaceuticals Announced Data from its Fully Human anti-SARS-CoV-2 Monoclonal Antibody Platform in an Oral Presentation at the World Antiviral Congress

Nov 23, 2022 7:00am EST

Tonix Pharmaceuticals to Participate in the A.G.P. Biotech Conference

Nov 22, 2022 7:00am EST

Tonix Pharmaceuticals Announces Oral Presentation at the World Vaccine and Immunotherapy Congress

Nov 21, 2022 7:00am EST

Tonix Pharmaceuticals Announces Oral Presentation at the World Antiviral Congress

  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • …Page 51
  • Next Pagearrow_forward
rss_feed News RSS
email icon Sign up for Email Alerts
twitter icon linkedin icon facebook icon
  • Contact Us
  • Privacy Policy
  • Terms of Use
  • Site Map

© 2023 Tonix Pharmaceuticals Holding Corp.